Alkeon Capital Management LLC Raises Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Alkeon Capital Management LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 633,845 shares of the biotechnology company’s stock after buying an additional 75,000 shares during the quarter. Alkeon Capital Management LLC owned 0.66% of Sarepta Therapeutics worth $79,161,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Thrivent Financial for Lutherans lifted its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after acquiring an additional 37,940 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock valued at $76,401,000 after purchasing an additional 6,992 shares in the last quarter. abrdn plc boosted its position in shares of Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after buying an additional 101,253 shares during the last quarter. Mizuho Markets Americas LLC increased its holdings in Sarepta Therapeutics by 22.3% in the 3rd quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock worth $49,839,000 after buying an additional 72,765 shares in the last quarter. Finally, Fiera Capital Corp raised its position in Sarepta Therapeutics by 4.3% in the 2nd quarter. Fiera Capital Corp now owns 382,645 shares of the biotechnology company’s stock worth $60,458,000 after buying an additional 15,606 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SRPT shares. Guggenheim lifted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC cut their target price on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price target on the stock. Finally, William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Trading Up 5.7 %

Shares of SRPT stock opened at $137.94 on Friday. The stock has a market capitalization of $13.18 billion, a price-to-earnings ratio of 110.35 and a beta of 0.81. The stock’s 50-day moving average price is $122.16 and its 200-day moving average price is $131.43. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.